Navigation Links
Schering-Plough CEO Buys $2 Million in Common Shares

KENILWORTH, N.J., April 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that Chairman and CEO Fred Hassan purchased just over $2 million of Schering-Plough common stock, or 110, 000 shares at an average purchase price of $18.26 per share.

"As I said when I announced my intention to purchase these shares in January, this investment in Schering-Plough reflects my long-term confidence in the company, its products -- including ZETIA and VYTORIN -- and our late- stage pipeline," said Hassan.

Hassan has said on January 18 that he intended to purchase the shares as soon as the transaction received legal clearance. That clearance was issued this morning, based upon first quarter earnings having been reported yesterday.

Full details of the purchase will be reported on a Form 4 filed with the SEC and available on Schering-Plough's Web site today or tomorrow.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
2. Schering-Plough Reports Financial Results for First Quarter of 2008
3. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
4. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
5. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
7. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
8. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
9. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
10. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
11. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group ... the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with ... qualified medical researchers and practitioners, experienced in administering stem cell protocols using highly ...
(Date:11/30/2015)... includes an MPP licen ... niversity , s Solid Drug Nanoparticle (SDN) Technology ; ... up through cost cuts of priority ... based anywhere in the world will have the right to make, use and distribute ... where licensees based anywhere in the world will have the right to make, use ...
(Date:11/30/2015)... 2015 Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... designed to create shareholder value. ... "Based on published reports, the total addressable market ... and Spherix will seek to secure fair and ...
(Date:11/30/2015)... 30, 2015 TapImmune, Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for ... it will be presenting at the 8 th ... at 2.30 PM PT. Dr. John N. Bonfiglio ... be giving the presentation and will join TapImmune management ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/27/2015)... YORK , Oct. 27, 2015 In ... major issues of concern for various industry verticals such ... is due to the growing demand for secure & ... in various ,sectors, such as hacking of bank accounts, ... for electronic equipment such as PC,s, laptops, and smartphones ...
Breaking Biology News(10 mins):